Metastatic Breast Cancer is the breast cancer that kills.
Our Bold Goal at Susan G. Komen® is to reduce breast cancer deaths by 50% in the U.S. by 2026. The key to reaching this goal is MBC research. In fact, it is pretty simple. Research cures cancer. Nothing else does.
In the Triangle, we have a unique opportunity to provide the breakthrough research needed to help reach our Bold Goal and increase the 5-year survivorship of those diagnosed with metastatic breast cancer.
It is research that will cure this disease, and until then, it is research that will transform MBC from terminal to chronic, giving patients and their families the priceless gift of time. But, time is of the essence.
When we first learned of metastatic breast cancer (MBC) in the 1970s, only 10% of women survived five years after diagnosis. Today, the five-year survival rate is 25%. It’s time to do better.
Komen® North Carolina Triangle to the Coast (NCTC) is launching a first-of-its-kind program to catalyze research between the world-class cancer research institutions in our backyard—Duke Cancer Institute and UNC Lineberger Comprehensive Cancer Center.
The new fund will ignite and fast track MBC research. By leveraging local expertise and removing research silos that slow progress, we will discover ways for patients to live well and longer with this disease.
Grants restricted to Duke and UNC projects will be targeted, cutting-edge, and provide researchers the opportunity to work together to enhance current work or develop new approaches.
Komen NCTC Catalyst for Collaboration Research Fund will expand current local research. Individual projects from Duke and UNC will also remain eligible for Komen Research Program funding. Over the past 10 years, Komen has invested more than $27 million in Triangle-based research.
How will it work?
The NCTC Catalyst for Collaboration Research Fund will launch with an initial goal to raise $5M over three years to support Triangle-based MBC research. As soon as there are $2M in commitments, Komen NCTC will open the granting process and accept applications. Only projects between Duke University and The University of North Carolina at Chapel Hill will be eligible.
Housed within the Komen Research Program, we will utilize our esteemed national peer-review process through the Komen Scientific Advisory Board to take advantage of a rigorous review and global perspective to drive the most critical research needs.
Death from MBC is unacceptable.
Leading Komen Scholars and young researchers at Duke and UNC have expressed great enthusiasm about the possibilities for real impact. Now, we must secure the funding to make this revolutionary collaborative research possible.
Ending it starts with you and your bold investment to the Komen NCTC Catalyst for Collaboration Research Fund. Research is hope for those fighting metastatic breast cancer today, and for those who will be diagnosed tomorrow.
Enough is enough. We must do everything we can to save lives.